U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.84-0.64 (-3.88%)
At close: 04:00PM EST
15.84 0.00 (0.00%)
After hours: 06:03PM EST

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000

Full Time Employees773

Key Executives

NameTitlePayExercisedYear Born
Dr. Stelios Papadopoulos Ph.D.Co-Founder & Independent Chairman98kN/A1948
Dr. Michael M. MorrisseyCEO, Pres & Director2.35M40.64M1961
Mr. Christopher J. SennerExec. VP & CFO1.06M2.86M1968
Mr. Jeffrey J. HessekielExec. VP, Gen. Counsel & Sec.916.91k8.28M1969
Mr. Patrick J. Haley M.B.A., MBAExec. VP of Commercial801.65k944.74k1976
Dr. Dana T. AftabExec. VP of Bus. OperationsN/AN/AN/A
Dr. Peter LambExec. VP of Scientific Strategy & Chief Scientific OfficerN/AN/A1961
Ms. Susan T. HubbardExec. VP of Public Affairs & Investor RelationsN/AN/AN/A
Mr. Gregg BernierVP of MarketingN/AN/AN/A
Ms. Laura DillardExec. VP of HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Corporate Governance

Exelixis, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.